Short answer
Xencor Inc (XNCR) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $51M (up 17.5% year over year) with net income of −$22M.
Q2 2026 key financials · XBRL
- Revenue
- $51M
- +17.5% YoY · +1034.2% QoQ
- Net income
- −$22M
- +29.5% YoY · +83.1% QoQ
- Operating margin
- -72.4%
- EPS (diluted)
- −$0.28
- +31.7% YoY · +83.6% QoQ
Source: XBRL data from the Xencor Inc (XNCR) Q2 2026 10-Q on SEC EDGAR. USD.
Xencor Inc Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin percentages disclosed in provided excerpt
- Portfolio spanning early- and mid-stage clinical programs, with three marketed medicines using XmAb technologies
- Disciplined portfolio management: advancing, partnering, or discontinuing programs based on clinical data and priorities
- No cash, operating cash flow, capital deployment, or updated guidance details disclosed in provided excerpt
Risk Factors
- Risk factors section not provided; supplied text covers Items 2–6 and signatures
- Trading-plan risk: Chief Scientific Officer’s arrangement covering 41,883 shares terminated June 23, 2026 before any sales
- Executive compensation change: Executive Severance Policy dated April 23, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xencor Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.